In the landscape of modern oncology, few medical strategies have undergone as significant a transformation as the management of early-stage prostate cancer. For decades, the diagnosis of prostate cancer—regardless of its aggressiveness—was almost reflexively met with immediate intervention, typically surgery or radiation. However, a landmark study of the Veterans Affairs Healthcare System (VAHCS) published in JAMA reveals a seismic shift in clinical practice. Between 2005 and 2024, the use of active surveillance for low- and favorable intermediate-risk prostate cancer has more than tripled, effectively ending the era of "overtreatment" that once defined the field.
The Core Findings: A Statistical Revolution
The study, led by Dr. Matthew R. Cooperberg of the University of California San Francisco (UCSF) and his colleagues, provides a comprehensive look at the clinical behavior of the nation’s largest integrated healthcare system. The data is stark: in 2005, only 27% of men diagnosed with low-risk prostate cancer within the VA system were managed via active surveillance. By 2024, that figure had climbed to an impressive 93%.
The shift was equally pronounced among men with favorable intermediate-risk prostate cancer, where the adoption of active surveillance rose from 14% to 61%. These numbers represent more than just incremental change; they signify a wholesale adoption of "watchful waiting" protocols that prioritize patient quality of life without compromising long-term survival outcomes.
The researchers analyzed 73,042 patients diagnosed with low- and favorable intermediate-risk prostate cancer over the two-decade period. Of these, 38,130 were initially placed on active surveillance or watchful waiting. This massive dataset offers a clear view into how clinical philosophy has evolved in response to better diagnostic tools and a more nuanced understanding of tumor biology.
A Chronology of Change: From Overtreatment to Precision Care
To understand the magnitude of this shift, one must look at the historical context of prostate cancer screening. For years, the widespread use of Prostate-Specific Antigen (PSA) testing led to the detection of thousands of "indolent" cancers—tumors that grow so slowly they would never have caused clinical symptoms during a patient’s lifetime.
In the early 2000s, the medical community frequently defaulted to radical prostatectomy or radiation for these slow-growing tumors. This approach often led to unnecessary complications, including urinary incontinence and erectile dysfunction, without providing a survival benefit.
- 2005–2010: The "Early Adoption" phase. Active surveillance was still a nascent concept, viewed with skepticism by many clinicians who feared that "doing nothing" might lead to a missed window of opportunity for curative treatment.
- 2011–2018: The "Evidence-Gathering" phase. Numerous studies began to demonstrate that for low-risk disease, the survival outcomes for active surveillance were statistically identical to those of immediate intervention. During this period, guidelines from organizations like the National Comprehensive Cancer Network (NCCN) began to lean heavily toward surveillance.
- 2019–2024: The "Institutionalization" phase. As seen in the VA data, the practice moved from being a niche option to the standard of care. The standardization of MRI-guided biopsies and more precise risk stratification tools allowed physicians to feel more comfortable in their decision to monitor rather than intervene.
Supporting Data: Dissecting the Variables
While the overall trend is one of widespread adoption, the study highlights critical nuances in patient demographics and institutional consistency. The researchers noted that across individual VA facilities, surveillance rates varied significantly, ranging from 23% to 93%. This variability suggests that while national guidelines are clear, the "culture" of individual medical centers remains a powerful factor in clinical decision-making.
A multivariable analysis of the data revealed the factors that influenced whether a patient was placed on surveillance:
- Age: Older patients were more likely to be placed on active surveillance, with odds increasing by 43% per decade. This reflects a clinical preference to avoid the side effects of invasive surgery in patients with shorter life expectancies.
- Diagnosis Date: The more recent the diagnosis, the higher the likelihood of being placed on active surveillance, confirming that clinical practice is trending toward this model globally.
- Demographic Disparities: The study identified that Black or African American men, as well as Hispanic or Latino patients, had lower odds of being placed on active surveillance compared to their white counterparts. These findings mirror broader disparities in healthcare access and clinical counseling that remain a priority for further research and intervention.
- Clinical Indicators: Unsurprisingly, patients with higher Grade Group (GG) scores or a higher percentage of positive-result biopsy cores were less likely to be on surveillance, indicating that doctors are correctly identifying when a cancer is moving past the "indolent" phase.
Official Responses and Clinical Perspectives
The medical community has largely hailed these findings as a triumph of evidence-based medicine. In an accompanying editorial in JAMA, Dr. Daniel E. Spratt of the University Hospitals Seidman Cancer Center noted that the shift is a direct result of "randomized trials, mature prospective cohorts, and unified guideline support."
Dr. Cooperberg, the study’s lead author, emphasized the philosophical shift in a UCSF press release: "Prostate cancer screening saves thousands of lives by finding aggressive cancers early, but it also detects many slow-growing cancers that do not spread, and should not be treated except in rare occasions. Many experts are recommending that we not even call these ‘cancers.’"
This perspective is crucial. By reframing the diagnosis, clinicians can alleviate the "anxiety-driven" decision-making that historically led patients to demand surgery, even when it wasn’t medically indicated. As Dr. Spratt observed, "Clinicians came to recognize that patient anxiety… is something they can address directly rather than a reason to expose a patient to the harms of treatment he does not need."
The Feasibility of Implementation
A major concern regarding the expansion of active surveillance has been the resource intensity of follow-up care—namely the need for frequent MRIs and biopsies. However, Dr. Grace Lee, a co-author of the study, argues that the model is highly scalable, even in resource-limited settings.
"With the caveat that active surveillance can be personalized to each patient… PSA generally should not be obtained more than every 6 months, and MRI/biopsy no more frequently than once per year," Dr. Lee explained. She noted that if repeat biopsies return negative results, the interval between screenings can be extended even further.
The essential, non-negotiable component, according to Dr. Lee, is the "confirmatory biopsy" conducted within 6 to 12 months of the initial diagnosis. This step is critical to ensure that a more aggressive tumor was not missed during the initial sampling. Once this baseline is established, the management process becomes much more manageable for both the patient and the healthcare system.
Implications for the Future of Oncology
The implications of this study reach far beyond the VA system. The data confirms that the "overtreatment" of prostate cancer is largely a problem of the past, at least within well-resourced, guidelines-driven institutions. The success of the VA’s transition provides a roadmap for private practice and community hospitals to follow.
- Standardization: The high rates of active surveillance in the VA show that when institutional protocols are aligned with evidence-based guidelines, clinicians can move past the financial and emotional pressures that once favored surgery.
- Addressing Disparities: The study underscores that while the average patient is receiving better care, specific ethnic and socioeconomic groups are still falling through the cracks. Future efforts must focus on ensuring that minority populations receive the same encouragement toward active surveillance as the general population.
- Patient Education: As the medical community moves toward "active monitoring," patient education becomes the primary tool for success. Patients must be empowered to understand that for certain prostate cancers, "active surveillance" is not "doing nothing"—it is a proactive, medically managed strategy to protect their quality of life.
As medicine continues to refine its ability to distinguish between benign and lethal disease, the story of prostate cancer management in the VA stands as a testament to the power of data to reform medical culture. By choosing to "watch and wait," clinicians are not retreating; they are evolving, ensuring that they provide the right treatment to the right patient at the right time—and, most importantly, knowing when to leave well enough alone.
